Skip Navigation LinksHome > September 2014 - Volume 20 - Issue 9 > Probiotic Mix VSL#3 Is Effective Adjunctive Therapy for Mild...
Inflammatory Bowel Diseases:
doi: 10.1097/MIB.0000000000000084
Original Clinical Articles

Probiotic Mix VSL#3 Is Effective Adjunctive Therapy for Mild to Moderately Active Ulcerative Colitis: A Meta-analysis

Mardini, Houssam E. MD, MPH*; Grigorian, Alla Y. MD, PhD

Supplemental Author Material
Collapse Box

Abstract

Background:

VSL#3 is a probiotic mix preparation reported to be effective in the treatment of mild to moderately active ulcerative colitis. We aimed to perform a systematic review of the literature and a meta-analysis of studies on its efficacy.

Methods:

The searched databases included PubMed, Scopus, and ScienceDirect. The Mantel–Haenszel method was used to pool the effect- ize across studies, and the odds ratios (ORs) and 95% confidence intervals (CIs) of experiencing a specific outcome were calculated.

Results:

Five studies with 441 patients were identified. The pooled remission rate was 49.4% (95% CI, 42.7–56.1). Only 3 low risk of bias studies with 319 patients met the inclusion criteria for further analysis. A total of 162 patients received 3.6 × 1012 CFU/d VSL#3, and 157 patients received placebo. A total of 95% of patients received concomitant therapies with 5-ASA and/or immunomodulators. The Ulcerative Colitis Disease Activity Index was used to define response and remission. A >50% decrease in the Ulcerative Colitis Disease Activity Index was achieved in 44.6% of the VSL#3-treated patients versus 25.1% of the patients given placebo (P = 0008; OR, 2.793; 95% CI, 1.375–5.676; number needed to treat = 4–5). The response rate was 53.4% in VSL#3-treated patients versus 29.3% in patients given placebo (P < 0001; OR, 3.03; 95% CI, 1.89–4.83; number needed to treat = 3–4). The remission rate was 43.8% in VSL#3-treated patients versus 24.8% in patients given placebo (P = 0007; OR, 2.4; 95% CI, 1.48–3.88; number needed to treat = 4–5). No serious side effects were reported.

Conclusions:

VSL#3, when added to conventional therapy at a daily dose of 3.6 × 1012 CFU/d, is safe and more effective than conventional therapy alone in achieving higher response and remission rates in mild to moderately active ulcerative colitis.

Copyright © 2014 Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.